A Phase 3 interventional study of Romosozumab and Placebo in Postmenopausal Osteoporosis, sponsored by Amgen. Completed at 218 sites in 24 countries. Open to female participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-08-28.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing romosozumab in Osteoporosis, Postmenopausal — 1 open to participants now, 2 under way, none of them phase 3. romosozumab · Osteoporosis, Postmenopausal.
Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, this one has the largest enrollment, is one of 3 that started in 2012, is one of 6 in phase 3, and was the 2nd registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 12 studies testing romosozumab in Osteoporosis, Postmenopausal is open now. Recruiting first, the newest first:
Massachusetts General Hospital
Ages 45+ · Women only
romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 55 Years to 90 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2012.
This study's enrollment of 7,180 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 268 across the 12 interventional studies. Of the 9 that completed or were terminated, 9 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
24 studies in Osteoporosis, Postmenopausal by Amgen: none open now, none under way, none of them phase 3. Of 24 finished, 23 (96%) have results posted.
Among the 24 studies in Osteoporosis, Postmenopausal by Amgen, this one is the 2nd largest by enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2012, is one of 14 in phase 3, and was the 12th registered.
Amgen’s Osteoporosis, Postmenopausal studies by the year they started, since 2004.
1 of the studies testing romosozumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, from their registry updates:
Among Amgen’s 24 in Osteoporosis, Postmenopausal:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if treatment with romosozumab is effective in preventing fractures in women with postmenopausal osteoporosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 210 mg romosozumab subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
Drug: Romosozumab · Drug: Denosumab
Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
Drug: Placebo · Drug: Denosumab
Administered by subcutaneous injection once a month (QM)
Also known as: AMG 785, EVENITY™
Administered by subcutaneous injection once a month (QM)
Administered by subcutaneous injection once every 6 months (Q6M)
Also known as: Prolia®
Percentage of Participants With New Vertebral Fracture Through Month 12
New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method. The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.
Time frame: 12 Months
Percentage of Participants With New Vertebral Fracture Through Month 24
New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method. The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.
Time frame: 24 months
Percentage of Participants With a Clinical Fracture Through Month 12
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.
Time frame: 12 Months
Percentage of Participants With a Nonvertebral Fracture Through Month 12
A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.
Time frame: 12 Months
Percentage of Participants With a Nonvertebral Fracture Through Month 24
A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date as recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.
Time frame: 24 Months
Percentage of Participants With a Clinical Fracture Through Month 24
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.
Time frame: 24 Months
Percentage of Participants With a Major Nonvertebral Fracture Through Month 12
A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.
Time frame: 12 Months
Percentage of Participants With a Major Nonvertebral Fracture Through Month 24
A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.
Time frame: 24 Months
Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 12
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4.
Time frame: 12 Months
Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4.
Time frame: 24 Months
Percentage of Participants With a Hip Fracture Through Month 12
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.
Time frame: 12 Months
Percentage of Participants With a Hip Fracture Through Month 24
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.
Time frame: 24 Months
Percentage of Participants With a Major Osteoporotic Fracture Through Month 12
Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.
Time frame: 12 Months
Percentage of Participants With a Major Osteoporotic Fracture Through Month 24
Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.
Time frame: 24 Months
Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 12
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.
Time frame: 12 Months
Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.
Time frame: 24 Months
Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and Month 12
Percent Change From Baseline In Bone Mineral Density at the Lumbar Spine at Month 24
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and Month 24
Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 12
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and Month 12
Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and Month 24
Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 12
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and Month 12
Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 24
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and Month 24
This study was conducted at 222 centers in Europe, Central/Latin America, Asia, North America, and Australia/New Zealand. The first participant enrolled on 15 March 2012 and the last participant enrolled on 06 December 2013.
| Milestone | Placebo/Denosumab | Romosozumab/Denosumab |
|---|---|---|
| Started | 3591 | 3589 |
| Received double-blind treatment | 3582 | 3575 |
| Completed double-blind period | 3205 | 3185 |
| Completed 24-month study period | 3032 | 2994 |
| Completed | 2892 | 2851 |
| Not completed | 699 | 738 |
| Withdrew: Withdrawal by subject | 352 | 390 |
| Withdrew: Death | 81 | 74 |
| Withdrew: Other | 70 | 70 |
| Withdrew: Adverse event | 63 | 61 |
| Withdrew: Lost to follow-up | 55 | 68 |
| Withdrew: Noncompliance | 52 | 27 |
| Withdrew: Administrative decision | 15 | 33 |
| Withdrew: Ineligibility determined | 5 | 8 |
| Withdrew: Protocol deviation | 4 | 3 |
| Withdrew: Requirement for alternative therapy | 2 | 4 |
New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method. The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.
| percentage of participants | Placebo | Romosozumab |
|---|---|---|
| Percentage of Participants With New Vertebral Fracture Through Month 12 | 1.8 | 0.5 |
New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method. The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.
| percentage of participants | Placebo/Denosumab | Romosozumab/Denosumab |
|---|---|---|
| Percentage of Participants With New Vertebral Fracture Through Month 24 | 2.5 | 0.6 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.
| percentage of participants | Placebo | Romosozumab |
|---|---|---|
| Percentage of Participants With a Clinical Fracture Through Month 12 | 2.5 | 1.6 |
A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.
| percentage of participants | Placebo | Romosozumab |
|---|---|---|
| Percentage of Participants With a Nonvertebral Fracture Through Month 12 | 2.1 | 1.6 |
A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date as recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.
| percentage of participants | Placebo/Denosumab | Romosozumab/Denosumab |
|---|---|---|
| Percentage of Participants With a Nonvertebral Fracture Through Month 24 | 3.6 | 2.7 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.
| percentage of participants | Placebo/Denosumab | Romosozumab/Denosumab |
|---|---|---|
| Percentage of Participants With a Clinical Fracture Through Month 24 | 4.1 | 2.8 |
A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.
| percentage of participants | Placebo | Romosozumab |
|---|---|---|
| Percentage of Participants With a Major Nonvertebral Fracture Through Month 12 | 1.5 | 1.0 |
A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.
| percentage of participants | Placebo/Denosumab | Romosozumab/Denosumab |
|---|---|---|
| Percentage of Participants With a Major Nonvertebral Fracture Through Month 24 | 2.8 | 1.9 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4.
| percentage of participants | Placebo | Romosozumab |
|---|---|---|
| Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 12 | 1.8 | 0.5 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4.
| percentage of participants | Placebo/Denosumab | Romosozumab/Denosumab |
|---|---|---|
| Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24 | 2.5 | 0.7 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.
| percentage of participants | Placebo | Romosozumab |
|---|---|---|
| Percentage of Participants With a Hip Fracture Through Month 12 | 0.4 | 0.2 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.
| percentage of participants | Placebo/Denosumab | Romosozumab/Denosumab |
|---|---|---|
| Percentage of Participants With a Hip Fracture Through Month 24 | 0.6 | 0.3 |
Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.
| percentage of participants | Placebo | Romosozumab |
|---|---|---|
| Percentage of Participants With a Major Osteoporotic Fracture Through Month 12 | 1.8 | 1.1 |
Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.
| percentage of participants | Placebo/Denosumab | Romosozumab/Denosumab |
|---|---|---|
| Percentage of Participants With a Major Osteoporotic Fracture Through Month 24 | 3.1 | 1.9 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.
| percentage of participants | Placebo | Romosozumab |
|---|---|---|
| Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 12 | 0.3 | 0.03 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.
| percentage of participants | Placebo/Denosumab | Romosozumab/Denosumab |
|---|---|---|
| Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24 | 0.5 | 0.03 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12 | 0.4 ± 0.1 | 13.1 ± 0.1 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Placebo/Denosumab | Romosozumab/Denosumab |
|---|---|---|
| Percent Change From Baseline In Bone Mineral Density at the Lumbar Spine at Month 24 | 5.5 ± 0.1 | 16.6 ± 0.1 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 12 | 0.3 ± 0.1 | 6.0 ± 0.1 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Placebo/Denosumab | Romosozumab/Denosumab |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24 | 3.2 ± 0.1 | 8.5 ± 0.1 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Placebo | Romosozumab |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 12 | 0.3 ± 0.1 | 5.5 ± 0.1 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Placebo/Denosumab | Romosozumab/Denosumab |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 24 | 2.3 ± 0.1 | 7.3 ± 0.1 |
Collected over Double-blind treatment period: 12 months; Overall study: 36 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 12-Month Double-blind Period: Placebo | — | 314/3,576 (8.8%) | 2,059/3,576 (57.6%) |
| 12-Month Double-blind Period: Romosozumab | — | 344/3,581 (9.6%) | 2,019/3,581 (56.4%) |
| 36-Month Study Period: Placebo/Denosumab | — | 733/3,576 (20.5%) | 2,434/3,576 (68.1%) |
| 36-Month Study Period: Romosozumab/Denosumab | — | 728/3,581 (20.3%) | 2,463/3,581 (68.8%) |
| Event | 12-Month Double-blind Period: Placebo | 12-Month Double-blind Period: Romosozumab | 36-Month Study Period: Placebo/Denosumab | 36-Month Study Period: Romosozumab/Denosumab |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 10/3576 | 19/3581 | 37/3576 | 44/3581 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 15/3576 | 6/3581 | 28/3576 | 22/3581 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 15/3576 | 6/3581 | 27/3576 | 21/3581 |
| Femur fractureInjury, poisoning and procedural complications | 7/3576 | 4/3581 | 19/3576 | 9/3581 |
| Atrial fibrillationCardiac disorders | 4/3576 | 6/3581 | 18/3576 | 17/3581 |
| Radius fractureInjury, poisoning and procedural complications | 5/3576 | 3/3581 | 17/3576 | 14/3581 |
| Urinary tract infectionInfections and infestations | 7/3576 | 4/3581 | 14/3576 | 17/3581 |
| Acute myocardial infarctionCardiac disorders | 4/3576 | 6/3581 | 10/3576 | 16/3581 |
| HypertensionVascular disorders | 5/3576 | 8/3581 | 12/3576 | 15/3581 |
| CataractEye disorders | 5/3576 | 4/3581 | 14/3576 | 13/3581 |
| Event | 12-Month Double-blind Period: Placebo | 12-Month Double-blind Period: Romosozumab | 36-Month Study Period: Placebo/Denosumab | 36-Month Study Period: Romosozumab/Denosumab |
|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 434/3576 | 468/3581 | 663/3576 | 668/3581 |
| NasopharyngitisInfections and infestations | 439/3576 | 460/3581 | 622/3576 | 651/3581 |
| Back painMusculoskeletal and connective tissue disorders | 380/3576 | 373/3581 | 573/3576 | 518/3581 |
| FallInjury, poisoning and procedural complications | 319/3576 | 255/3581 | 539/3576 | 484/3581 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 299/3576 | 278/3581 | 407/3576 | 417/3581 |
| HypertensionVascular disorders | 260/3576 | 219/3581 | 411/3576 | 384/3581 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 210/3576 | 184/3581 | 329/3576 | 321/3581 |
| HeadacheNervous system disorders | 206/3576 | 235/3581 | 270/3576 | 293/3581 |
| Urinary tract infectionInfections and infestations | 142/3576 | 130/3581 | 263/3576 | 244/3581 |
| Viral upper respiratory tract infectionInfections and infestations | 227/3576 | 206/3581 | 263/3576 | 230/3581 |
The full analysis set consisted of all randomized participants.
| Age, Continuous(years) | Placebo/Denosumab | Romosozumab/Denosumab | Total |
|---|---|---|---|
| Mean | 70.8 ± 6.9 | 70.9 ± 7.0 | 70.9 ± 7.0 |
| Age, Customized(Participants) | Placebo/Denosumab | Romosozumab/Denosumab | Total |
|---|---|---|---|
| < 65 years | 757 | 768 | 1525 |
| ≥ 65 years | 2834 | 2821 | 5655 |
| Sex: Female, Male(Participants) | Placebo/Denosumab | Romosozumab/Denosumab | Total |
|---|---|---|---|
| Female | 3591 | 3589 | 7180 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Placebo/Denosumab | Romosozumab/Denosumab | Total |
|---|---|---|---|
| Hispanic or Latino | 1416 | 1427 | 2843 |
| Not Hispanic or Latino | 2175 | 2162 | 4337 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo/Denosumab | Romosozumab/Denosumab | Total |
|---|---|---|---|
| White | 2052 | 2063 | 4115 |
| Asian | 441 | 425 | 866 |
| Black or African American | 74 | 77 | 151 |
| American Indian/Alaska Native | 63 | 64 | 127 |
| Native Hawaiian/Other Pacific Islander | 1 | 0 | 1 |
| Multiple | 59 | 60 | 119 |
| Other | 901 | 900 | 1801 |
| Prevalent Vertebral Fracture Strata per Randomization(Participants) | Placebo/Denosumab | Romosozumab/Denosumab | Total |
|---|---|---|---|
| Yes | 205 | 204 | 409 |
| No | 3386 | 3385 | 6771 |
| Age Strata per Randomization(Participants) | Placebo/Denosumab | Romosozumab/Denosumab | Total |
|---|---|---|---|
| < 75 years | 2471 | 2470 | 4941 |
| ≥ 75 years | 1120 | 1119 | 2239 |
Showing the first 100 of 218 sites across 24 countries. Choose a country and city above to see the rest.
Ran from Mar 2012 to primary completion in Dec 2015, 44 months.
Results were first posted in Nov 2018, 2 years 10 months after primary completion. A results delay was requested in Mar 2016.
Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 44 months is above that.
Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romosozumab
Osteoporosis, Postmenopausal →